HeyJaredResearch To Practice | Oncology Videos
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management…
- Indexed episodes, last 90 days
- 77
- Latest publication
- Sep 14, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 6, 2026
Latest episodes
Low-Grade Serous Ovarian Cancer — Rapid Case Review: Microlearning Activity 2 (opens the original)
Read excerpt
Featuring perspectives from Dr Rachel N Grisham, including the following topics: Case: A woman in her early 40s with recurrent low-grade serous ovarian cancer (LGSOC) and prior treatment with a MEK inhibitor receives avutometinib/defactinib on the RAMP 301 trial (0:00) Case: A woman in her early 70s with recurrent KRAS-mutated LGSOC receives avutometinib/defactinib and develops muscle weakness (10:03) Case: A woman in her late 70s with KRAS-mutated recurrent LGSOC develops congestive heart failu
Low-Grade Serous Ovarian Cancer — 5-Minute Journal Club: Microlearning Activity 1 (opens the original)
Read excerpt
Featuring perspectives from Dr Rachel N Grisham, including the following topics: Mechanism, clinical evidence and practical use of avutometinib with defactinib for recurrent low-grade serous ovarian cancer (LGSOC) (0:00) A Phase III trial of letrozole alone as front-line treatment for LGSOC (11:11) Current and future role of avutometinib with defactinib for LGSOC (19:23) A Phase II/III trial of trametinib for recurrent LGSOC: Biomarker analyses and clinical implications (21:37) CME information a
Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (opens the original)
Read excerpt
Featuring an interview with Prof Andreas Hochhaus, including the following topics: Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00) Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09) Potential mechanisms of adverse events documented with TKIs (10:23) Recent survey of patients with CML regarding goals of therapy and clinical implications; c
Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus (Companion Faculty Lecture) (opens the original)
Read excerpt
Featuring a slide presentation and related discussion from Prof Andreas Hochhaus, including the following topics: · Historical evolution of the treatment landscape for chronic myeloid leukemia and goals of clinical care (0:00) · Current therapeutic landscape and available long-term data (10:22) · Mechanism of action of asciminib and key findings from the ASC4FIRST study (16:50) · Key clinical trial data from the ASC4START study and factors in treatment selection (23:15) · Investigational therapi
Endometrial Cancer — Microlearning Activity 3: Proceedings from an Independent Satellite Symposium during the SGO Annual Meeting on Women's Cancer (opens the original)
Read excerpt
Featuring perspectives from Dr Floor J Backes, Dr Matthew A Powell and Dr Ritu Salani, moderated by Dr Salani, including the following topics: Case: A woman in her late 60s with recurrence of metastatic estrogen receptor-positive endometrial cancer enrolls in a trial of CDK4/6 inhibition with an aromatase inhibitor 1 year into maintenance dostarlimab after carboplatin/paclitaxel/dostarlimab and has no evidence of disease 3 years later (0:00) Adding a PARP inhibitor to immunotherapy and chemother
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.